Literature DB >> 11592106

Upregulation of tenascin and TGFbeta production in a type II alveolar epithelial cell line by antibody against a pulmonary auto-antigen.

W A Wallace1, S E Howie.   

Abstract

Type II alveolar epithelial cells express a 70-90 kDa antigen to which circulating auto-antibodies have been previously identified in patients with cryptogenic fibrosing alveolitis (CFA). In vitro experiments have been conducted with a rabbit polyclonal antibody raised to this auto-antigen, and the type II epithelial cell line A549. This study examined possible effects that interaction of this antibody with type II epithelial cells might have on the production of cytokines and extracellular matrix components that may be important in the pathogenesis of CFA. There was a significant increase in TGFbeta and tenascin, but not IL4, production by the A549 cells after culture with the immune serum. Further experiments showed that after 72 hours in culture, the antibody decreased A549 cell number in a complement-dependent process, which appeared to be cytostatic rather than cytolytic. These results indicate in vitro biological activity for this antibody and suggest a possible in vivo role for auto-antibody to type II epithelial cells in the pathogenesis of CFA. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592106     DOI: 10.1002/path.916

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  Oxidative damage and TGF-β differentially induce lung epithelial cell sonic hedgehog and tenascin-C expression: implications for the regulation of lung remodelling in idiopathic interstitial lung disease.

Authors:  Paul M Fitch; Sarah E M Howie; William A H Wallace
Journal:  Int J Exp Pathol       Date:  2010-10-29       Impact factor: 1.925

Review 3.  B-lymphocyte lineage cells and the respiratory system.

Authors:  Atsushi Kato; Kathryn E Hulse; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2013-04       Impact factor: 10.793

4.  Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients.

Authors:  Jianmin Xue; Daniel J Kass; Jessica Bon; Louis Vuga; Jiangning Tan; Eva Csizmadia; Leo Otterbein; Makoto Soejima; Marc C Levesque; Kevin F Gibson; Naftali Kaminski; Joseph M Pilewski; Michael Donahoe; Frank C Sciurba; Steven R Duncan
Journal:  J Immunol       Date:  2013-07-19       Impact factor: 5.422

5.  Autoantibodies in patients with chronic obstructive pulmonary disease.

Authors:  Carol A Feghali-Bostwick; Aneal S Gadgil; Leo E Otterbein; Joseph M Pilewski; Michael W Stoner; Eva Csizmadia; Yingze Zhang; Frank C Sciurba; Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2007-11-01       Impact factor: 21.405

6.  Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses.

Authors:  Rehan A Kahloon; Jianmin Xue; Arpit Bhargava; Eva Csizmadia; Leo Otterbein; Daniel J Kass; Jessica Bon; Makoto Soejima; Marc C Levesque; Kathleen O Lindell; Kevin F Gibson; Naftali Kaminski; Gunjan Banga; Chester V Oddis; Joseph M Pilewski; Frank C Sciurba; Michael Donahoe; Yingze Zhang; Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2013-04-01       Impact factor: 21.405

7.  C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.

Authors:  Louis J Vuga; John R Tedrow; Kusum V Pandit; Jiangning Tan; Daniel J Kass; Jianmin Xue; Divay Chandra; Joseph K Leader; Kevin F Gibson; Naftali Kaminski; Frank C Sciurba; Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

8.  Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.

Authors:  Michael Donahoe; Vincent G Valentine; Nydia Chien; Kevin F Gibson; Jay S Raval; Melissa Saul; Jianmin Xue; Yingze Zhang; Steven R Duncan
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

9.  Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations.

Authors:  Tejaswini Kulkarni; Vincent G Valentine; Fei Fei; Thi K Tran-Nguyen; Luisa D Quesada-Arias; Takudzwa Mkorombindo; Huy P Pham; Sierra C Simmons; Kevin G Dsouza; Tracy Luckhardt; Steven R Duncan
Journal:  PLoS One       Date:  2021-11-23       Impact factor: 3.240

10.  Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis.

Authors:  Peter Heukels; Jennifer A C van Hulst; Menno van Nimwegen; Carian E Boorsma; Barbro N Melgert; Jan H von der Thusen; Bernt van den Blink; Rogier A S Hoek; Jelle R Miedema; Stefan F H Neys; Odilia B J Corneth; Rudi W Hendriks; Marlies S Wijsenbeek; Mirjam Kool
Journal:  Respir Res       Date:  2019-10-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.